Klaipedos universiteto ligonine VšĮ — Clinical Trial Site

43 Registered trials

9 Currently recruiting

Organisation

Klaipedos universiteto ligonine VšĮ

Location

Klaipeda, Lithuania

Identifier

ORG-100043231

Address

Liepojos G. 45, Klaipedos M. Sav., 92288, Lithuania

Departments

#2600: Chemotherapy
#7401
2600: Chemotherapy
440011 orthopaedic
440011: orthopaedic
8083
8101
8601 Klaipeda Hospital
Cardio
Cardiology Clinic
Cardiology Department
Department of Neurological Diseases and Rehabilitation
Department of Oncohematology
Department of Rheumatology
Department of Urology
Gastroenterologijos
Hospitalizacijos klinika, Ambulatorinių konsultacijų skyrius
I kardiologijos skyrius
Klaipeda Seamen's hospital( #1)
Klaipedos Universitetine Ligonine
LT10005: Klaipeda Hospital
n/a
NA
Neurology center
None
Oncology Chemotherapy department
orthopedic
orthopedist traumatologist
Public Institution Department of Oncology
Rheumatology department
Urology
Vidaus ligų klinika

Clinical trials at this site (43)

Search interface

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Adult patients of either gender with active moderate to 5
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A Phase 2, Open-Label, Single-Arm, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix … Pending

2023-509255-14-01 Advanced prostate cancer 4
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (P… Pending

2025-522471-28-00 psoriatic arthritis (PsA) 5
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Moderately to Severely Active Ulcerative Colitis 4 2025-11-27
REGN7508 versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults. Recruiting

2025-520478-20-00 Thromboembolic disease 5 2025-11-05
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A study to test if SRSD107 prevents venous thromboembolism events and how safe it is Recruiting

2024-519688-16-00 venous thromboembolism 4 2025-08-07
A study to assess the efficacy and safety of efgartigimod PH20 SC in adults with systemic sclerosis (eSScape) Recruiting

2024-514539-67-00 Systemic Sclerosis 4 2025-06-27
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active… Ended

2024-516213-20-00 Psoriatic arthritis 5 2025-03-25
A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab tr… Ended

2024-513160-25-00 Melanoma and Non-small-cell lung cancer 5 2024-10-30
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended

2023-503655-10-00 Systemic Lupus Erythematosus (SLE). 5 2023-11-20
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin… Ended

2023-507522-16-00 Metastatic Esophageal or Gastric Cancer 5 2023-05-22
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
A Phase 3 Single-Arm Study of UGN-102 for Treatment of LG IR NMIBC Ended

2023-506680-34-00 Non-Muscle Invasive Bladder Cancer 5 2022-03-24
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24